UroGen Pharma Ltd. Ordinary Shares

URGN IL0011407140

💰
Capitalization
Small-cap

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

🔗
Website
https://www.urogen.com
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
22
🙍
Insiders
2
Person Price Shares Total Published Completed
Smith Jason Drew
SR OFF 		19.11
USD 		1,520
Sold 		29,047
USD 		07/09/2025 08/09/2025
Schoenberg Mark
CMO 		19.11
USD 		871
Sold 		16,645
USD 		07/09/2025 08/09/2025
Schoenberg Mark
CMO 		17.69
USD 		10,000
Sold 		176,900
USD 		11/08/2025 11/08/2025
Schoenberg Mark
CMO 		19.14
USD 		5,149
Sold 		98,552
USD 		28/07/2025 28/07/2025
Smith Jason Drew
SR OFF 		19.14
USD 		7,522
Sold 		143,971
USD 		28/07/2025 28/07/2025
Schoenberg Mark
CMO 		7.37
USD 		5,162
Sold 		38,044
USD 		08/06/2025 09/06/2025
Schoenberg Mark
CMO 		11.14
USD 		759
Sold 		8,455
USD 		31/01/2025 31/01/2025
Schoenberg Mark
CMO 		11.14
USD 		1,896
Sold 		21,121
USD 		31/01/2025 31/01/2025
Smith Jason Drew
SR OFF 		11.14
USD 		3,354
Sold 		37,364
USD 		31/01/2025 31/01/2025
Schoenberg Mark
CMO 		11.14
USD 		1,896
Sold 		21,121
USD 		31/01/2025 31/01/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include UroGen Pharma Ltd. Ordinary Shares to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Last 52W Low 52W High All-Time Low All-Time High β
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Schoenberg Mark 13 687,714.57 52,901.12 31/01/2024 08/09/2025
Smith Jason Drew 9 353,704.84 39,300.54 31/01/2024 08/09/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.